The Wall Street Journal

August 19, 2005

HEALTH
DOW JONES REPRINTS
This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers, use the Order Reprints tool at the bottom of any article or visit:
http://www.djreprints.com/.

• See a sample reprint in PDF format.
• Order a reprint of this article now.

Merck Press Release
August 19, 2005

Merck & Co. issued the following press release after the jury reached a verdict in the Vioxx trial involving the death of Robert Ernst:

WHITEHOUSE STATION, N.J. -- Aug. 19, 2005 -- Merck & Co., Inc. is disappointed a state court jury in Brazoria County, Texas, returned a verdict in favor of the plaintiff in the VIOXX(R) product liability lawsuit Ernst v. Merck. Merck will appeal the verdict.

"We believe that the plaintiff did not meet the standard set by Texas law to prove VIOXX caused Mr. Ernst's death," said Jonathan Skidmore of Fulbright & Jaworski, a member of Merck's defense team. "There is no reliable scientific evidence that shows VIOXX causes cardiac arrhythmias, which an autopsy showed was the cause of Mr. Ernst's death, along with coronary atherosclerosis."

"This case did not call for punitive damages," added Skidmore. "Merck acted responsibly -- from researching VIOXX prior to approval in clinical trials involving almost 10,000 patients -- to monitoring the medicine while it was on the market -- to voluntarily withdrawing the medicine when it did."

Merck is examining various bases for appeal, including:

-- Allowing opinion testimony to be given to the jury by unqualified experts,

-- Allowing opinion testimony that was not based on a reliable scientific basis as required by Texas law,

-- Allowing evidence with no relevance to the issues of the case, which unfairly prejudiced the jury, and

-- Allowing undisclosed surprise witness and expert testimony contrary to Texas law.

"We believe that we have strong points to raise on appeal and are hopeful that the appeals process will correct the verdict," said Kenneth C. Frazier, senior vice president and general counsel of Merck. "Our appeal is about fundamental rights to a fair trial."

"There are other VIOXX cases coming to trial and we will vigorously defend them one by one over the coming years," Frazier added.

About Merck

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines in more than 20 therapeutic categories. The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. For more information, visit www.merck.com.

Source: BusinessWire

Return to main article.1

URL for this article:
http://online.wsj.com/article/0,,SB112447886602718426,00.html

Hyperlinks in this Article:
(1) http://online.wsj.com/article/0,,SB112447069284018316,00.html?mod=article-outset-box
Copyright 2005 Dow Jones & Company, Inc. All Rights Reserved
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit http://www.djreprints.com/.